C1.1.1. Introduction: The CRSR is a Core component of the NSBCC, the NCI UCLA-ICMIC, UCLA Institute for Molecular Medicine (IMED) and Crump Institute for Molecular Imaging. The prime objective of the CRSR is to provide positron emitting radioisotopes and radiolabeled PET probes and biomarkers for investigators in NSBCC, ICMIC, IMED and the Crump Institute. The core is directed by Dr. Satyamuthy. The CRSR was established in 1971 by the Department of Energy as a part of IMED. It currently houses two RDS -112 negative ion cyclotron (CTI, Knoxville, TN) systems that are supported with a wide array of target systems, semiautomated and automated systems producing various radiolabeled precursors for synthesizing molecular probes and biomarkers, and for producing final labeled products as discussed below in detail. The CRSR has more than enough capacity to meet the needs of NSBCC. It has been both scientifically profitable and personally rewarding for the CRSR staff to expand our interactions with the physical and biological sciences community at UCLA. With the NSBCC program, that extension will now include Caltech and ISB researchers. In fact, for some of the NSBCC Projects preliminary results were obtained through joint Caltech/UCLA collaborations. Approximately 10% of our radiosynthesis work over the initial NSBCC funding period will be NSCBB-related, with about 50% of the rest of the work supported by various other NCI supported research and educational programs as discussed in the proposal. In reality, the DoE support supplements, to some extent, programs that are under the aegis of the NSBCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA119347-05
Application #
7918209
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$48,816
Indirect Cost
Name
California Institute of Technology
Department
Type
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Bunck, David N; Atsavapranee, Beatriz; Museth, Anna K et al. (2018) Modulating the Folding Landscape of Superoxide Dismutase?1 with Targeted Molecular Binders. Angew Chem Int Ed Engl 57:6212-6215
Poovathingal, Suresh Kumar; Kravchenko-Balasha, Nataly; Shin, Young Shik et al. (2016) Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics. Small 12:1425-31
Masui, Kenta; Shibata, Noriyuki; Cavenee, Webster K et al. (2016) mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays 38:839-44
Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2016) Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol 33:161-8
Das, Samir; Nag, Arundhati; Liang, JingXin et al. (2015) A General Synthetic Approach for Designing Epitope Targeted Macrocyclic Peptide Ligands. Angew Chem Int Ed Engl 54:13219-24
Zuckerman, Jonathan E; Gale, Aaron; Wu, Peiwen et al. (2015) siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther 25:53-64
Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2015) mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment. Brain Pathol 25:755-9
Deyle, Kaycie M; Farrow, Blake; Qiao Hee, Ying et al. (2015) A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1. Nat Chem 7:455-62
Hu-Lieskovan, Siwen; Homet Moreno, Blanca; Ribas, Antoni (2015) Excluding T Cells: Is ?-Catenin the Full Story? Cancer Cell 27:749-50
Heath, James R (2015) Nanotechnologies for biomedical science and translational medicine. Proc Natl Acad Sci U S A 112:14436-43

Showing the most recent 10 out of 135 publications